TESARO (NASDAQ:TSRO) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Other analysts also recently issued reports about the company. Cantor Fitzgerald lifted their price target on TESARO from $57.00 to $68.00 and gave the company a “positive” rating in a research note on Monday, October 22nd. Argus downgraded TESARO from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Citigroup decreased their price target on TESARO from $100.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, August 29th. Bank of America lifted their price target on TESARO from $35.00 to $38.00 and gave the company a “neutral” rating in a research note on Tuesday, September 11th. Finally, Cowen restated a “hold” rating and issued a $38.00 price target on shares of TESARO in a research note on Monday, October 22nd. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $73.25.

TESARO stock opened at $36.83 on Tuesday. The company has a current ratio of 3.40, a quick ratio of 2.83 and a debt-to-equity ratio of 3.74. TESARO has a 1-year low of $23.41 and a 1-year high of $88.83. The company has a market capitalization of $1.92 billion, a P/E ratio of -4.02 and a beta of 1.35.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.62) by $0.13. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The firm had revenue of $64.40 million for the quarter, compared to the consensus estimate of $71.84 million. During the same period in the previous year, the business earned ($0.47) earnings per share. The company’s revenue for the quarter was down 54.9% compared to the same quarter last year. On average, equities analysts anticipate that TESARO will post -10.87 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV raised its holdings in shares of TESARO by 20.0% in the second quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock worth $468,000 after acquiring an additional 1,752 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of TESARO by 5.0% in the second quarter. Rhumbline Advisers now owns 39,787 shares of the biopharmaceutical company’s stock worth $1,769,000 after acquiring an additional 1,885 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of TESARO by 13.4% in the third quarter. Commonwealth Equity Services LLC now owns 18,822 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 2,218 shares during the last quarter. Trellus Management Company LLC raised its holdings in shares of TESARO by 20.0% in the second quarter. Trellus Management Company LLC now owns 13,819 shares of the biopharmaceutical company’s stock worth $615,000 after acquiring an additional 2,300 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of TESARO by 163.5% in the third quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 2,445 shares during the last quarter.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: Risk Tolerance and Your Investment Decisions

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.